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Abstract
Background: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3
dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior.
Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we
investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal
C57BL/6 mice.
Methods: Depressive-like behavior in C57BL/6J mice was assessed by the forced swim test. Expression of cytokines
and IDO mRNA in OHSCs was measured by real-time RT-PCR and cytokine protein was measured by enzyme-linked
immunosorbent assays (ELISAs). p38 MAPK phosphorylation was analyzed by western blot.
Results: Intracerebroventricular (i.c.v.) administration of Tat (40 ng) induced depressive-like behavior in the absence
of sickness. Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at
6 h. This effect was potentiated by pretreatment with IFNg. Tat also induced the synthesis and release of TNFa and
IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide
synthase (iNOS) and the serotonin transporter (SERT). Tat had no effect on endogenous synthesis of IFNg.T o
explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated
protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment. SB 202190 significantly decreased IDO
expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-
6, iNOS and SERT.
Conclusion: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that
depends upon activation of p38 MAPK. Targeting IDO itself or the p38 MAPK signaling pathway could provide a
novel therapy for comorbid depressive disorders in HIV-1-infected patients.
Background
The risk of major depressive disorder (MDD) in human
immunodeficiency virus (HIV)-infected patients is signif-
icantly greater than that in the general population [1,2].
Although highly active antiretroviral therapy (HAART)
appears to suppress viral replication, there is a high
level of microglial activation in the central nervous
system (CNS) of the post HAART-treated patients [3],
indicating that eliminating virus may not stop the pro-
cess of HIV-induced ongoing inflammation in the brain.
It has long been known that virus infected monocytes
are able to invade the brain and induce a local inflam-
matory chain reaction that involves the synthesis and
release of proinflammatory cytokines by infected and
non-infected macrophages and microglia. In addition,
infected cells can shed viral proteins such as gp120 and
Tat which can activate glial cells by themselves and
therefore contribute to the propagation of inflammation
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any medium, provided the original work is properly cited.[4,5]. Although the production of inflammatory media-
tors by glial cells exposed to HIV-1 proteins has been
mainly studied in the context of AIDS-related dementia
[6,7], there is still limited evidence that HIV-1 proteins
administered into the brain can induce depressive-like
behavior in preclinical models with laboratory rodents.
Rats injected with gp120 into the lateral ventricle of the
brain present with signs of sickness associated with
increased production of proinflammatory cytokines.
Some of these behavioral alterations, such as the
decreased preference for a saccharin solution, mimic the
anhedonia observed in depressed patients [8,9]. Intracer-
ebral administration of HIV-1 Tat to mice induces
depressive-like behavior in mice as measured by
increased immobility in the forced swim and tail suspen-
sion tests, together with increased expression of brain
proinflammatory cytokines [10].
We have already established that development of
inflammation-associated depression is dependent on
activation of the tryptophan degrading enzyme indolea-
mine 2,3 dioxygenase (IDO) by proinflammatory cyto-
kines such as IFNg and TNFa [11,12]. IDO degrades
tryptophan (Trp) into kynurenine (KYN) which can be
further metabolized into neurotoxic metabolites such as
3-hydroxykynurenine and quinolinic acid (QUIN) [13].
In addition to developing depressive-like behaviors, Tat-
treated mice also display increased IDO expression in
their brains [10]. The occurrence of neuropsychiatric
disorders in HIV-1 seropositive patients presenting with
symptoms of neuro-AIDS is associated with activation
of IDO in peripheral macrophages, as evidenced by
decreased levels of circulating Trp and increased plasma
levels of both KYN and the macrophage activation mar-
ker neopterin [14]. Confirmation that IDO activation
also takes place in the brain of HIV-infected patients
has been obtained since IDO enzymatic activity is
increased in the brain of HIV-infected patients with
HIV-associated dementia (HAD) [15]. IDO expression is
up-regulated in monocytic cells in brain tissue of both
patients with HIV-1 encephalitis (HIVE) [16] and mon-
keys infected with simian immunodeficiency virus ence-
phalitis (SIVE) [17]. Furthermore increases in brain
QUIN are associated with progression of HIV infection
[18]. Brain expression of IDO during HIV infection cer-
tainly contributes to immunotolerance since administra-
tion of the IDO competitive inhibitor 1-methyl
tryptophan enhances elimination of virus-infected
macrophages in mice with HIVE [16].
There is evidence that HIV-1 Tat can induce IDO
expression in various cell types. This is particularly the
case in macrophages [19,20] but also in astrocytes
exposed to HIV-1 clade B Tat [21]. We have demon-
strated that organotypic hippocampal slice cultures
(OHSCs) offer a reliable model for investigating
neuroimmune interactions and for studying the mechan-
isms of IDO activation [22]. Here we have used this
model to assess whether Tat alone or in conjunction
with IFNg can induce IDO expression. We chose IFNg
s i n c et h i sc y t o k i n ei st r a d i t i onally regarded as the pri-
mary inducer of IDO [23]. IFNg is elevated in the brains
of patients with HIVE and has been hypothesized to
play a role in the pathophysiology of HAD [24]. IFNg
synergizes with Tat to enhance chemokine expression,
which in turn can amplify the inflammatory responses
within the CNS of patients with AIDS-related neurologi-
cal disorders [25]. However, IFNg-independent activa-
tion pathway has also been reported in response to LPS
in primary microglia and murine slices [22,26]. Addi-
tionally, the IFNg-independent up-regulation of IDO
expression was recently demonstrated in HIV-infected
human macrophages [27]. It is unknown whether this
property of IDO induction extends to OHSCs exposed
to HIV proteins such as Tat. Furthermore, the precise
mechanisms responsible for IFNg-independent induction
of IDO following exposure to Tat are not clearly
understood.
Activation of IDO is not the sole mechanism that
could be responsible for inflammation-associated
depression. By reuptake of serotonin (5-HT) with high
affinity in presynaptic neurons, the sodium-dependent
serotonin transporter (SERT) contributes to the regula-
tion of 5-HT neurotransmission [28]. Several cytokines,
including IFNa,I F N g,I L - 1 b and TNFa,a r ea b l et o
increase expression of SERT [29,30]. Additionally, a
recent study reported that HIV-1 clade B and C Tat dif-
ferentially induce SERT expression in dendritic cells
[31]. For this reason, we included SERT in the possible
targets of HIV-1 Tat in the in vitro model of OHSCs.
HIV-1 Tat mediates its biological functions by activat-
ing a variety of signaling pathways and transcription fac-
tors. The p38 mitogen-activated protein kinase (MAPK)
is activated by Tat in a variety of cell types, including
monocytes [32,33], macrophages [34], astrocytes [35]
and the THP-1 cell line [36]. Since p38 MAPK is
required for IDO expression in THP-1 cells [37], we
investigated whether this signaling pathway also med-
iates Tat-induced expression of IDO in OHSCs. In the
present study, we show that Tat induces the expression
of IDO and synergizes with exogenous IFNg to increase
IDO induction in OHSCs and the effect of Tat is
mediated by p38 MAPK activation.
Methods
Reagents
Recombinant Tat 1-72 was provided by Professor Avin-
dra Nath through a contract with the University of Ken-
tucky. Stock solutions of Tat 1-72 were prepared in
phosphate buffered saline (PBS) (1ug/ul) and stored at
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Page 2 of 12-80°C until use. Recombinant murine IFNg (cat# 315-05)
was from PeproTech, Inc. Heat-inactivated horse serum
(cat# SH30074.03), Hank’s balanced salt solution (HBSS,
cat# SH30030.03) and minimal essential media (MEM)
(cat# SH30024.02) were all from Hyclone. Gey’s
balanced salt solution (GBSS, cat# G9779) was from
Sigma, D-glucose (cat# 15023-021) was from GibcoBRL
and the kits for enzyme-linked immunosorbent assays
(ELISA) were obtained from R&D Systems (Wiesbaden,
DE). TRIzol reagent was purchased from Invitrogen Life
Technologies (Carlsbad, CA). Reagents for RT-PCR
were all from Applied Biosystems as follows: high capa-
city cDNA reverse transcription kit (cat# 4374967); RT-
PCR primers for IDO (cat# Mm00492586_m1), TNFa
(cat# Mm00443258_m1), IL-6 (cat# Mm00446190_m1),
the inducible isoform of nitric oxide synthase (iNOS)
(cat# Mm00440485_m1) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; cat# Mm999999_g1).
Antibodies specific for p38 (cat# 9212) and phosphory-
lated p38 (p- p38, cat# 9211) were purchased from Cell
Signaling Biotechnology (Danvers, MA), whereas the
secondary horseradish peroxidase (HRP)-linked rabbit
anti-mouse antibody (NA93 4 V )w a so b t a i n e df r o mG E
Healthcare Biosciences (Piscataway, NJ). The p38 MAPK
inhibitor SB 202190 (cat# 559397) was from EMD Che-
m i c a l s ,I n c .( U S A ) .P r o t e i nw a sm e a s u r e dw i t has t a n -
dard Bradford assay kit (cat# 500-0113, 0114, 0115) and
Immun-Blot polyvinylidene difluoride (PVDF, cat# 162-
0177) membranes were from Bio-RAD (Hercules, CA).
ECL Western blotting detection reagents (cat#
RPN2106V1, RPN2106V2) were obtained from GE
Healthcare Little Chalfont (Bucks, UK).
Mice
All animal care and use procedures were conducted in
a c c o r d a n c ew i t ht h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (National Research Council) and
approved by the Institutional Animal Care and Use
Committee. Experiments conducted in vivo were per-
formed on 12-week-old male C57BL/6J mice obtained
from a colony raised in our laboratory. Mice were indi-
vidually housed in standard shoebox cages, with wood
shavings as litter, in a temperature- (23°C) and humid-
ity- (45-55%) controlled environment with a 12/12 h
modified dark-light cycle (lights on 10:00 P.M.-10:00 A.
M.). Food and water were available ad libitum.
Intracerebroventricular (i.c.v.) Cannulation
Mice were surgically implanted with a single guide can-
nula (Plastics One, Roanoke, VA) directed toward the
lateral ventricle, As previously described [10]. The guide
cannulas were kept clean and covered using a screw on
cannula dummy for mice (Plastics One, Roanoke, VA).
Coordinates for placement of the guide cannula were
1.5 mm lateral, 0.6 mm posterior, and 1.3 mm dorsal
with respect to bregma. These coordinates placed the
guide cannula 1 mm dorsal to the lateral ventricle. Mice
were allowed to recover 2 weeks before treatment and
initiation of behavioral tests. After recovery, mice were
slowly injected over 1 min i.c.v. with phosphate buffered
saline (PBS) or Tat (40 ng) in a volume of 1 μl. This
dose of Tat was selected on its ability to reliably induce
IDO expression in human astrocytes [38].
Forced swim test (FST)
The forced swim test was conducted at 24 h post i.c.v.
injection of Tat for a five-min period and the mice were
video recorded for future analysis. Immobility was
defined as passive floating behavior or any movement
necessary for the mouse to keep its head above water, as
described previously [10].
Organotypic hippocampal slice cultures
Murine hippocampal slice cultures were prepared using
the static interface culture method [22]. Briefly, 6- to 8-
day-old C57BL/6J mice were decapitated. The brains
and meninges were removed, followed by separation of
the hippocampus from both hemispheres. Hippocampi
were dissected and transverse slices (350 μmi nt h i c k -
n e s s )w e r ep r e p a r e du s i n gaM c I l w a i nt i s s u ec h o p p e r
(Campden Instruments Ltd, UK). Slices were placed for
1 h at 4°C into GBSS supplemented with 2 mg/ml
D-glucose and were then transferred onto porous (0.4
μm) transparent membrane inserts (30-mm in diameter;
Millipore) with five slices on each insert. Inserts were
then placed into six-well culture plates. Each well con-
tained 1.2 ml of nutrient medium composed of 25%
heat-inactivated horse serum, 25% HBSS and 50% MEM
supplemented with 25 mM D-glucose. Neither antibio-
tics nor anti-mycotics were used. Plates were maintained
in a humidified CO2 incubator (5% CO2, 95% atmo-
s p h e r i ca i r )a t3 7 ° C .M e d i u mw a sc h a n g e de v e r y2 - 3
days. The MEM medium was changed so that it con-
tained only 5% horse serum and 25 mM D-glucose on
the day that Tat or control medium was added. At var-
ious times following addition of Tat, supernatants were
collected and stored at -80°C for measurement of cyto-
kines. Slices were washed 3 times with cold PBS and
stored at -80°C for isolation of total cellular RNA and
for western blotting. Slice viability was evaluated using
both propidium iodide (PI) staining and the amount of
lactate dehydrogenase (LDH) released into the culture
medium by CytoTox
96 non-radioactive cytotoxicity kit.
Reverse transcription and real-time RT-PCR
Total cellular RNA from the hippocampus and cultured
slices was extracted in TRIzol reagent, as previously
described [22]. Total mRNA (1-2 μg) was reverse
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reverse transcription kit from Ambion. Samples were
analyzed in duplicate. Data were analyzed using the
comparative threshold cycle method, as described else-
where (Applied Biosystems user bulletin no.2).
Enzyme-linked immunosorbent assays (ELISAs)
TNFa and IL-6 were measured in OHSCs supernatants
with validated specific ELISA assays [22]. Briefly, 100 μl
of each sample were added in duplicate to ELISA plates
pre-coated with an anti-TNFa or IL-6 capture antibody.
Recombinant murine TNFa and IL-6 standards ranged
from 0 to 1,000 pg/ml. The lower assay limit of detec-
tion was 16 pg/ml. Absorbance was measured on an
OPTImax ELISA plate reader. TNFa and IL-6 concen-
trations are expressed as picograms per milliliter.
Western blot analysis
Western blotting experiments were conducted as pre-
viously described [26], with minor modifications. Briefly,
slices were lysed in cold lysis buffer. Equal amounts of
protein (40 μg) were separated on 10% polyacrylamide
gels. Proteins were then transferred from the gel to
PVDF membranes using a Bio-Rad Laboratories Mini
Protein 3 system. After treating PVDF membranes with
blocking buffer (TBS/0.1% Tween20 (TBST) containing
2% BSA) for 1 h at room temperature, they were incu-
bated overnight at 4 C with blocking buffer containing
primary antibodies specific for phosphorylated p38 or
p38, (1:1000 dilution). Membranes were washed exten-
sively with TBST and then incubated for 1 h at room
temperature with a secondary antibody coupled to
horseradish peroxidase (HRP)-conjugated sheep anti-
mouse IgG antibodies at a dilution of 1:2000 in blocking
buffer. Finally, membranes were washed extensively with
TBST and developed with an enhanced chemilumines-
cence ECL Western Blot Detection Reagent. Blots were
covered with transparency film and then inserted into a
Fujifilm LAS-4000 System Configured for multifunc-
tional analysis (Fujifilm, Life Science, Stamford, USA).
Densitometric analysis of autoradiograms was performed
using publically available IMAGE-J software from the
National Institutes of Health (Bethesda, MD). Densito-
metric summaries were expressed as ratios of phos-
phorylated p38 to total p38.
Statistical analysis
Data were analyzed using a one-way (treatment) or
two-way (pretreatment × treatment) ANOVA, followed
by a post hoc pairwise multiple comparison using
Fischer’s LSD test if the interaction was significant. All
data are presented as means ± SEM. Differences were
considered significant if the probability reached a level
of 0.05 or less.
Results
Tat induces depressive-like behavior in C57BL/6J mice in
the absence of sickness
Mice were treated with i.c.v. PBS or Tat (40ng). At 24 h
post Tat, sickness and depressive-like behavior were
assessed by body weight loss and FST, respectively. Con-
sistent with our previous findings [10], the 24 h changes
in body weight did not differ according to treatment
(Figure 1A, p >0.05). Tat-treated mice displayed
increased immobility in the FST at 24 h post-treatment
compared to control mice (Figure 1B, p < 0.05).
HIV-1 Tat induces biochemical markers of inflammation-
associated depression in murine OHSCs
W er e c e n t l yf o u n dt h a tc e n t r a li n j e c t i o no fH I V - 1T a t
(40 ng) increased brain IDO and cytokine steady-state
transcripts at 4 h [10]. Here we determined whether the
expression of IDO and cytokines response to Tat occurs
i nm u r i n eO H S C sa si td o e si nt h eC N Sin vivo.B a s e d
on the in vivo response to central injection of Tat [10],
the time point of 6 h was selected for carrying out dose-
response experiments to determine the effect of Tat on
cytokine and IDO expression. Slices were exposed to 4,
40 and 400 ng/slice of Tat on day 10 in culture. As
shown in Figure 2, Tat significantly increased TNFa, IL-
6 and iNOS at the mRNA level (p <0 . 0 5 )i nad o s e -
dependent manner, with a maximum at 400 ng/slice.
Tat-induced increases in TNFa and IL-6 mRNA expres-
sion were paralleled by a concomitant increase in pro-
tein production (Figure 2, p < 0.05). Increased iNOS
mRNA was not associated with any detectable increase
in nitrite levels at the 6 h time point (data not shown).
Induction of SERT mRNA reached a maximum at 4 ng/
slice (Figure 2, p < 0.05).
Figure 1 LPS administered via the i.c.v. route induces
depressive-like behavior. Mice were injected i.c.v. with either PBS
or Tat (40 ng). (A) Body weight was measured before and 24 h after
injection and expressed as body weigh change. (B) Duration of
immobility was quantified during a 5 min forced swim test that
took place 24 h following administration of Tat or PBS. Data
represent mean ± SEM (n = 6 mice/group). * p < 0.05 compared
to PBS.
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Page 4 of 12Figure 2 Tat induces TNFa, IL-6, iNOS and SERT expression in OHSCs in a dose-dependent manner.T a ta tad o s eo f4 ,4 0a n d4 0 0n g /
slice was added to the medium after 10 days in culture. Tissue and media were collected 6 h later. Average Ct values for 4, 40 and 400 ng/slice
Tat were, respectively, for TNFa: 22.54 ± 0.68, 19.85 ± 0.43, 18.53 ± 0.43; IL-6: 21.34 ± 0.21, 19.88 ± 0.03, 19.29 ± 0.12; iNOS: 21.69 ± 0.14, 19.92 ±
0.14, 19.42 ± 0.26; SERT: 28.45 ± 0.04, 27.91 ± 0.02, 28.09 ± 0.15. Levels of TNFa and IL-6 (pg/ml) were measured in the supernatant by ELISA.
Data represent the mean ± SEM (n = 3 in each group). Bars labeled with different letters (a, b, c or d) are significantly different from each other
at p < 0.05.
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slice Tat for 2, 6 and 12 h on day 10 of culture. As
shown in Figure 3, the greatest expression of both
mRNA and protein for TNFa occurred at 2 h (p < 0.05)
and 6 h (p < 0.05), respectively. IL-6 mRNA peaked at 6
h( p <0 . 0 5 )a n dg r a d u a l l yd e c r e a s e da t1 2h .I L - 6c o n -
centration in the culture medium increased after 6 h (p
<0 . 0 5 )a n dr e a c h e dam a x i m u ma t1 2h( p <0 . 0 5 ) .
iNOS and SERT mRNA increased at 6 h (p <0 . 0 5 )a n d
peaked at 12 h (p < 0.05), but there was no concomitant
increase in nitrite levels at any time point (data not
shown). We also used real-time RT-PCR to determine
whether Tat induces IDO steady-state transcripts in
OHSCs as it does in vivo. To determine an optimal dose
for Tat-induced expression of IDO, OHSCs were treated
with 4, 40 and 400 ng/slice of Tat for 6 h. As shown in
Figure 4A, IDO mRNA expression could be detected at
4 ng/slice Tat and peaked at 40 ng/slice Tat (p <0 . 0 5 ) .
Kinetic studies were then carried out in which OHSCs
were exposed to Tat (40 ng/slice) for 2, 6 and 12 h. As
shown in Figure 4B, IDO mRNA could not be detected
in OHSCs prior to addition of Tat (40 amplification
cycles). However, IDO expression was significantly
induced by Tat at 6 h (p < 0.05) with no further
increase at 12 h. This effect was similar in intensity to
that of exogenous IFNg (10 ng/ml, Figure 4C, p < 0.05).
Moreover, pretreatment of OHSCs with the same dose
of IFNg 24 h before Tat markedly amplified IDO
responses to Tat (Figure 4C, p < 0.01). However, the
Tat-induced expression of IDO did not require endo-
genous synthesis of IFNg because no IFNg mRNA could
be detected at 6 h in Tat-stimulated slices (40 amplifica-
tion cycles, data not shown).
p38 MAPK is required for HIV-1 Tat-induced IDO
expression
In accordance with the results of others on the effects of
Tat on p38 MAPK in various cell types [32-36], we con-
firmed that HIV-1 Tat can activate p38 MAPK in
OHSCs. Slices were treated with Tat for 15, 30, 60 and
120 min respectively and the lysates were analyzed for
phospho-p38 activity by Western blot analysis. We
found that Tat induced significant phosphorylation of
p38 MAPK as early as 15 min (Figure 5A, p < 0.05)
with a maximum at 60 min (Figure 5A, p < 0.05).
To determine whether p38 MAPK is involved in Tat-
induced IDO expression, the p38 MAPK inhibitor SB
202190 was employed. We previously established that
30 μM SB 202190 significantly suppresses cytokine
expression at both the mRNA and protein levels in
response to LPS stimulation (data not shown). The dose
of 30 uM was therefore selected for further experiments
on Tat-induced IDO expression. Slices were pretreated
with SB 202190 (30 μM) for 30 min before stimulation
with Tat for another 6 h. SB 202190 abrogated the Tat-
induced expression of IDO, IL-6, iNOS and SERT tran-
scripts, although this effect was only partial for TNFa
mRNA (Figure 5B, p < 0.01). SB 202190 also fully
blocked the Tat-induced release of cytokine proteins in
the slice supernatants (Figure 5B, p < 0.01). Importantly,
neither Tat nor SB 202190 affected viability of the cells,
as determined by measuring both PI staining and release
of lactate dehydrogenase into the culture medium (data
not shown). These data clearly demonstrate that the p38
MAPK signaling pathway is necessary for the Tat-
induced expression of both proinflammatory cytokines
and IDO.
Discussion
Results of the present experiments establish that HIV-1
Tat induces depressive-like behavior in vivo and induces
production of proinflammatory cytokine in vitro in mur-
ine OHSCs and increases expression of IDO and SERT.
These changes are dependent on activation of the p38
MAPK signaling pathway.
Our in vivo data show that Tat increases the duration
of immobility in the forced swim test in mice without
inducing any sickness, as measured by the lack of body
weight loss. These data are in agreement with already
published findings from our group on depressogenic
activity of Tat [10]. The mechanisms of the depresso-
genic activity of Tat were further investigated in vitro.
Compared to primary cultures of brain cells, OHSCs
have the advantage of preserving the cellular and con-
nective organization as well as several fundamental in
vivo-like characteristics such as glial-neuronal interac-
tions [39,40]. Although this preparation has previously
been used for studying the detrimental effects of proin-
flammatory cytokines on long-term potentiation in the
rat system [41,42], OHSCs have rarely been used for the
investigation of neuroimmune interactions. Our previous
experiments demonstrated that long term culture of
OHSCs can be reliably used to study neuroimmune
mechanisms of induction of IDO [22]. We therefore
employed OHSCs in the present experiments to study
the mechanisms involved in the expression of IDO by
Tat.
Depression is an important comorbid condition of
HIV infection. We previously demonstrated that IDO,
the first and rate-limiting enzyme in the synthesis of
KYN from the precursor of Trp, is both sufficient and
necessary to mediate depressive-like behavior in
response to either acute or chronic activation of the
immune system in mice [43,44]. Moreover, the increase
in brain IDO activity is invariably preceded by enhanced
expression of IDO mRNA, which can therefore be used
as a surrogate marker of IDO activation [26,43,44].
Therefore, in the present study, we examined the effects
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Page 6 of 12Figure 3 Tat induces TNFa, IL-6, iNOS and SERT expression in OHSCs in a time-dependent manner. Hippocampal slices were treated with
Tat (40 ng/slice) and tissue and media were collected at various times. Average Ct values at 2, 6 and 12 h were, respectively, for TNFa: 18.24 ±
0.76, 20.42 ± 0.75, 23.32 ± 1.01; IL-6: 21.08 ± 0.19, 19.88 ± 0.03, 21.98 ± 0.31; iNOS: 28.47 ± 1.91, 19.92 ± 0.14, 19.08 ± 0.25; SERT: 32.42 ± 0.28,
27.91 ± 0.02, 27.50 ± 0.18. Levels of TNFa and IL-6 (pg/ml) were measured in the supernatant by ELISA. Data represent the mean ± SEM (n = 3
in each group). Bars labeled with different letters (a, b, c or d) are significantly different from each other at p < 0.05.
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Page 7 of 12Figure 4 Tat induces IDO expression in OHSCs and this effect is potentiated by pretreatment with IFNg. (A) 4, 40 and 400 ng/slice Tat
were added to the medium after 10 days in culture. Tissue was collected 6 h following addition of Tat. Average Ct values for 4, 40 and 400 ng/
slice Tat for IDO were, respectively, 35.54 ± 0.29, 32.60 ± 0.39, 32.92 ± 0.30. (B) Hippocampal slices were treated with Tat (40 ng/slice) for 2, 6
and 12 h. Average Ct values at 2, 6 and 12 h for IDO were, respectively, 40.00 ± 0.00, 32.60 ± 0.39, 32.61 ± 0.25. Bars represent the mean ± SEM
(n = 3 in each group). Bars labeled with different letters (a or b) are significantly different from each other at p < 0.05. (C) Slices were
preincubated with medium alone or with IFNg (10 ng/ml) for 24 h, and this was followed by addition of 40 ng/slice Tat. Slices were collected 6
h later. Average Ct values for Tat, IFNg and Tat + IFNg were, respectively: 32.54 ± 0.37; 32.56 ± 0.25; 29.76 ± 0.37. Data represent the mean ±
SEM (n = 3 in each group). Bars labeled with different letters (a or b) are significantly different from each other at p < 0.05. * p < 0.05, ** p <
0.01 compared to medium control; ## p < 0.01 compared to Tat or IFNg treatment.
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Page 8 of 12Figure 5 p38 MAPK activation mediates Tat-induced expression of proinflammatory cytokines, iNOS, SERT and IDO in OHSCs. (A) Tat
induces Thr180/Tyr182 phosphorylation of p38 MAPK MAPK as early as 15 min with a maximum at 60 min in OHSCs. Hippocampal slices were
treated with Tat (40 ng/slice) at 15, 30, 60 and 120 min, and cell lysates were collected for p38 MAPK phosphorylation analysis by Western blot.
A representative Western blot showing results with hippocampal slices incubated with Tat at the above time points is shown, followed by
densitometric analysis of Western blots from three independent experiments. Densitometric data were calculated as ratio of phosphorylated p38
MAPK to total p38 MAPK. Bars labeled with different letters (a, b or c) are significantly different from each other at p < 0.05. (B) The p38 MAPK
inhibitor, SB 202190, abrogates Tat-induced expression of IDO, iNOS, SERT and proinflammatory cytokines. Hippocampal slices were treated with
SB 202190 (30 μM) for 30 min and then incubated with or without Tat (40 ng/slice) for 6 h. SB 202190 inhibited Tat-induced IDO, iNOS, SERT,
TNFa and IL-6 expression. Data represent the mean ± SEM (n = 3 in each group). ** p < 0.01 compared to medium control; ## p < 0.01
compared to Tat + SB treatment. SB = SB 202190.
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HIV-1 Tat protein significantly up-regulates IDO
mRNA expression in OHSCs. These results are consis-
tent with previous studies that describe Tat-mediated
induction of the IDO expression in other types of cells
[19-21]. These in vitro data are also in accordance with
our in vivo results showing that Tat induced depressive-
like behavior is associated with increased expression of
IDO in the brain [10]. Taken together, these data pro-
vide the first evidence to indicate that activation of IDO
in response to Tat stimulation in the brain could be a
key event in the switch from sickness to depressive-like
behavior.
IFNg is considered to be the prototypical inducer of
IDO in a variety of cells [23] as well as in clinical situa-
tions in which inflammation-associated depression
occurs [45]. Additionally, IFNg is increased in the brain
during HIV infection [24] and synergizes with Tat to
play a critical role in the pathogenesis of HAD [25]. It is
well documented that monocytes/macrophages/micro-
glia can produce IFNg [46-48]. However, IDO expres-
sion appears to be up-regulated in an IFNg-independent
manner in HIV-infected human macrophages [27]. IFNg
protein remained undetectable in HIV-infected human
macrophage supernatants while IDO expression
increased [27]. Our data indicate that IDO induction by
Tat does not necessarily require synthesis of IFNg
because no IFNg transcripts could be detected at 6 h.
These observations are in accordance with the results
obtained by Boasso et al. [49]. Boasso et al. reported
that blockade of either type I or type II IFNs by antibo-
dies was ineffective in preventing the induction of IDO
in human peripheral blood mononuclear cells exposed
to R5- or X4-trophic HIV. Therefore, our data extend
the developing concept that IDO can be induced by Tat
in an IFNg-independent mechanism.
Addition of Tat to OHSCs induced the synthesis and
release of proinflammatory cytokines. These cytokines
are well known to stimulate HIV-1 replication and con-
tribute to HIV pathogenesis [50,51]. Increased expres-
sion of proinflammatory cytokines in the brain is
observed in HIV-1 infected patients [52]. Tat also can
up-regulate cytokine expression, such as IL-1b and
TNFa, in peripheral blood macrophages, CNS-derived
cell lines and primary astrocytes, microglia [53,54] and
human monocytes [55]. The large increase in proinflam-
matory cytokine expression could mediate IDO induc-
tion by Tat. Both in vivo and in vitro studies have
shown that IDO induction is associated to IL-1b.F o r
instance, pretreatment in vivo with the anti-inflamma-
tory tetracycline derivative minocycline attenuates LPS-
induced expression of brain IL-1b, indicating that IL-1b
probably participates in LPS-induced expression of brain
IDO [44]. A synergistic activation of IDO by IL-1b,
TNF-a and IL-6 has been reported in human monocytic
THP-1 cells exposed to LPS [37]. We observed that IL-
1b mRNA can be induced by Tat in OHSCs (data not
shown). However, this induction does not lead to release
of IL-1b protein if exogenous ATP is not added to the
culture. This is because ATP is necessary for processing
and release of the mature IL-1b protein [56]. In the
absence of IL-1b, the most likely mediators of IFNg-
independent IDO induction in OHSCs are TNF-a and
IL-6. IDO induction has been shown to be mediated
mainly by TNF-a, but not by IL-6 in human monocytic
THP-1 cell cultures exposed to immune stimulation
[57]. However, IL-6 can synergize with TNF-a to
increase IDO activity [37]. The exact cytokine signaling
pathways that are predominantly involved in the pro-
duction of IDO in response to Tat in OHSCs remain to
be elucidated.
In addition to IDO induction by Tat, we observed a
robust induction of SERT mRNA in response to Tat.
This finding indicates that OHSCs can serve as a reli-
able in vitro model for investigating the possible contri-
bution of serotonin re-uptake mechanisms in comorbid
depressive disorders in HIV-infected patients. Whether
this change at the mRNA level translates into functional
changes in SERT remains to be established. This is an
important perspective since differences in the expression
and function of SERT are well known to affect many
human and mouse quantitative traits, including anxiety-
and depression-related behaviors [58].
To elucidate the signaling pathways that mediate Tat-
induced IDO expression, we examined whether Tat con-
tributes to overexpression of IDO by activating p38
MAPK. This signaling pathway has been shown to be
required for IDO expression in THP-1 cells following
LPS stimulation [37]. Moreover, HIV-1 Tat protein has
been reported to activate p38 MAPK in a variety of
cells, including monoctyes [32,33], macrophages [34],
astrocytes [35] and the human THP-1 cell line [36]. We
therefore tested the possibility that Tat-induced p38
promotes expression of IDO in OHSCs. SB 202190, a
highly selective, potent and cell permeable inhibitor of
p38 MAPK [59], was employed to inhibit p38 activation.
It binds within the ATP pocket of the active kinase with
aK d of 38 nM, as measured in recombinant human
p38, and selectively inhibits both the p38a and b iso-
forms. We observed that SB 202190 significantly inhib-
ited Tat-induction of IDO in OHSCs, which is
consistent with the possibility that p38 may be involved
in the development of Tat-induced depressive-like
behavior.
The demonstration of an inhibitory effect of SB
202190 on Tat-induced changes in OHSCs does not
mean p38 MAPK signaling is directly responsible for
these effects. Activation of p38 MAPK could act
Fu et al. Journal of Neuroinflammation 2011, 8:88
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Page 10 of 12indirectly via NFkB activation [60,61] or AP-1 activity at
both the transcriptional and post-transcriptional levels
[62]. The human IDO promoter region contains multi-
ple AP-1 and NFkB sites [37]. Therefore, the possibility
that other transcription factors are involved in Tat-
induced IDO expression cannot be dismissed. However,
our data clearly demonstrate that Tat-induced IDO
expression in OHSCs is mediated, at least in part,
through a p38-dependent mechanism.
In conclusion, results of the present studies demon-
strate that p38 MAPK is potently involved in HIV-1
Tat-induced IDO expression. These studies provide
further evidence for targeting the brain IDO and p38
MAPK signaling pathway in the treatment of depressive
disorders associated with HIV infection.
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